Top Health Tech Companies in San Diego, CA (409)
Optum, part of the UnitedHealth Group family of businesses, is a global organization that delivers care, aided by technology to help millions of people live healthier lives. The work you do with our team will directly improve health outcomes by connecting people with the care, pharmacy benefits, data and resources they need to feel their best. Here, you will find...
.jpg)
Optum's Top Stability & Growth Strengths
Strong Revenue Growth: Optum’s consolidated revenue expanded from $253.0B in 2024 to $270.6B in 2025, indicating continued top-line growth. Multi‑year reporting also highlights ongoing increases at the consolidated level even as segment performance diverges.
Diversified Revenue Streams: Performance is spread across three businesses, with Optum Rx delivering substantial gains, Optum Insight growing modestly, and Optum Health contracting. This mix shows pharmacy and technology services helping sustain overall scale despite softness in care delivery.
Cost & Operational Efficiency: Operating performance improved in 2026 as Optum’s operating income rose year over year to about $4B in Q2 alongside reported gains in technology and clinical operations. UnitedHealth also raised its 2026 adjusted EPS outlook, signaling confidence in execution.
Our purpose ensures that patients remain at the center of all we do. We live our purpose by sourcing the best science in the world; partnering with others in the healthcare system to improve access to our medicines; using digital technologies to enhance our drug discovery and development, as well as patient outcomes; and leading the conversation to advocate for...
Pfizer's Top Stability & Growth Strengths
Product Line Growth: Growth across non‑COVID medicines such as Eliquis, Padcev, the Vyndaqel family, Lorbrena, Nurtec/Vydura and oncology biosimilars has been robust. Launched and acquired products are showing sustained double‑digit operational gains, adding meaningful momentum.
Resilient & Sustainable Growth: Excluding COVID products, the underlying portfolio delivered mid‑single‑digit operational growth in 2025 and continued at a similar pace in early 2026, more than offsetting part of the COVID‑related decline. Reported revenue also returned to modest year‑over‑year growth in the first half of 2026, indicating stabilization.
Future-Ready Strategy: Management raised the midpoint of 2026 revenue guidance and continues to invest heavily in a broad late‑stage pipeline. This posture signals confidence that newer launches and acquired assets can drive the next leg of growth.
Schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions and services for pharmaceutical, biotechnology, and materials science research. The predictive power of Schrödinger's software allows scientists to accelerate their research and development, reduce research costs, and make novel discoveries.
Schrödinger, Inc.'s Top Stability & Growth Strengths
Strong Revenue Growth: Recent results indicate total revenue increased year over year in 2025 and continued to rise in the latest reported quarter. Guidance and quarterly updates point to ongoing top-line expansion even as mix shifts occur.
Resilient & Sustainable Growth: Underlying annual contract value expanded and accelerated in 2026, with management indicating continued growth despite the transition to hosted licensing. This suggests the core subscription base is strengthening even when reported revenue timing varies.
Diversified Revenue Streams: Growth is visible in both the software business and the milestone-driven drug discovery segment. The latter stepped up meaningfully in recent periods, complementing steady software momentum.
ZS is a management consulting and technology firm that partners with companies to improve life and how we live it. We transform ideas into impact by bringing together data, science, technology and human ingenuity to deliver better outcomes for all. Founded in 1983, ZS has more than 15,000+ employees in over 40 offices worldwide.
ZS's Top Stability & Growth Strengths
Strong Hiring & Retention: Hiring and headcount are expanding, with disclosures of 15,000+ global employees, thousands of new hires, and third‑party estimates indicating continued workforce growth. Available evidence also points to active internal mobility and a recent increase in active job postings.
Market Expansion: Geographic and client footprints are broadening, with 40+ offices and 1,700+ customers across 170+ countries alongside concrete investments in new and expanded locations such as Hyderabad and Kingston. These moves indicate scaling delivery capacity in major capability centers and new regions.
Innovation-Driven Growth: The offering mix is shifting toward AI, data, technology, and platforms, including proprietary solutions and product capabilities. Strategic moves such as Salesforce-focused acquisitions and collaborations, plus a Tulip solution partnership, extend capabilities beyond traditional consulting.
ERG is a leading U.S. based, privately held, independent clinical research site company, and provider of clinical development services with an expertise in early and late stage neuroscience drug development. With 21 wholly owned clinical sites and 5 affiliated sites, we conduct in-patient and out-patient phase I-IV clinical research studies. ERG has 340+ in-patient beds, a large and growing database...
Cortica is a rapidly growing healthcare company pioneering a unique and effective approach to treating neurodevelopmental conditions including autism spectrum disorder, speech and language delays, sensory processing disorder and other conditions that impact brain development. Harnessing insights and technologies from emerging neuroscience, Cortica brings together clinical specialists from a range of disciplines to design and deliver comprehensive care to children...
Family Health Centers of San Diego provides caring, affordable, high-quality health care and supportive services throughout San Diego County. Its offerings include primary and specialty care, behavioral health, dental and vision services, rehabilitation, substance-use treatment, urgent care, pharmacy services, and mobile medical care. It serves everyone, with a special commitment to uninsured, low-income, and medically underserved people. The organization serves...
Vividion Therapeutics, Inc. is a biotechnology company focused on transforming the future of human health through the creation of highly selective small molecule medicines that drug traditionally inaccessible targets. The company is advancing a broad, diversified pipeline of multiple, selective small molecule therapeutics for highly sought-after disease-causing target proteins in oncology and immunology. The company’s cutting-edge platform was spun out...
.png)
Plantible Foods is a B2B food technology company with the goal to develop the most functional and applicable plant-based protein in the world using scalable and sustainable aqua-farming and extraction technologies
For over 240 years, Takeda’s propensity to evolve has driven the next generation of innovation, and as a future-focused organization, we’re continuing to drive forward with endurance in our steadfast pursuit to achieve the best outcomes for our patients in a rapidly changing world. We have been preparing for this period of value creation by investing in data, digital and...
Takeda's Top Stability & Growth Strengths
Strong Market Position & Advantage: Takeda is consistently placed among the global top 15–20 by revenue and is a clear category leader in GI/IBD, plasma-derived therapies, and dengue vaccines with broad international authorizations and WHO support. Subcutaneous ENTYVIO and new oncology approvals like FRUZAQLA broaden real‑world use and extend reach.
Profitability: Reported FY2025 operating profit rose 19.3% year over year and EPS nearly doubled despite a slight revenue decline, supported by lower amortization and restructuring expense. Core profitability remained broadly stable as Growth & Launch Products expanded their share.
Future-Ready Strategy: Management is investing through FY2026 to convert a late‑stage pipeline (e.g., oveporexton, rusfertide, zasocitinib) into multiple launches, with Growth & Launch Products prioritized as near‑term engines. A multi‑year transformation and efficiency program targeting significant savings by FY2028 is intended to fund launches and strengthen competitiveness.
BMR Health Services, Inc. is a California-based Non-Public agency providing allied healthcare professionals to clients in the United States.
Aroa Biosurgery is a soft-tissue regeneration company that develops, manufactures, and distributes medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Committed to 'unlocking regenerative healing for everybody,' the company leverages its proprietary AROA ECM™ technology—a novel extracellular matrix biomaterial derived from ovine forestomach—to create regenerative tissue substitutes that significantly improve patient outcomes.
Clinically AI is an intelligence platform for Behavioral Healthcare and Long Term Care workflows in Clinical Documentation, Chart Auditing, and more. When partnered with Clinically, you will have a fine tuned AI workforce that understands your organization and your EHR. Products: Clinical Notes AI - The Chart Aware Ambient Scribe Comply - Real time qualitative auditing and post discharge full chart...
MeBe is a provider of evidence-based therapies for children with autism and other special needs. Their mission is to empower families, professionals, and communities by educating and training them on evidence-based approaches, offering play-filled, research-based care across multiple disciplines.
Acuity Eye Group provides best-in-class eye care services and comprehensive treatment to the people in their communities, utilizing a modern approach to keep patients feeling and seeing their best.
Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for health care professionals powered by a network of people and technology. With more than 20,000 Team Schein Members worldwide, the Company's network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our Business, Clinical, Technology,...
Henry Schein's Top Stability & Growth Strengths
Strong Market Position & Advantage: Regulators, company filings, and independent coverage characterize Henry Schein as a top full‑service dental distributor with global scale and Fortune 500 standing. Its role in an FTC‑recognized oligopoly and breadth across distribution and software reinforce durable competitive advantages.
Resilient & Sustainable Growth: Recent results indicate steady year‑over‑year increases in sales and EPS, and management has reaffirmed guidance for modest top‑line and EBITDA growth. Share repurchases and a multi‑year operating‑income improvement program support a measured compounding profile.
Future-Ready Strategy: The company is investing in higher‑growth technology and value‑added services and pursuing AI‑enabled initiatives alongside a defined multi‑year operating plan. Portfolio moves in software, digital solutions, and specialty offerings are positioned to create switching costs and embed workflows in practices.
TrueMed is a payments tool (think PayPal for HSA/FSA) that allows health + wellness brands to accept HSA/FSA funds. We are partnering with leading health and wellness brands such as CrossFit, Magic Mind, and DB Method to drive increased AOV (30%+ for many leading merchants), retention (40% increase in month 2 retention) and LTV. Our implementations are simple (official Shopify payments...
Eli Lilly and Company engages in the discovery, development, manufacture, and sale of products in pharmaceutical products business segment. For more than a century, we have stayed true to a core set of values – excellence, integrity, and respect for people – that guide us in all we do: discovering medicines that meet real needs, improving the understanding and management of...
Eli Lilly and Company's Top Stability & Growth Strengths
Strong Market Position & Advantage: By market value and category leadership in incretins, Lilly sits at or near the top of global pharma. Mounjaro/Zepbound are redefining obesity/diabetes, with Mounjaro becoming the world’s best‑selling prescription drug in early 2026.
Strong Revenue Growth: Results show outsized, volume-led acceleration, with Q1 2026 revenue reaching $19.8B. Management also raised 2026 sales guidance to about $82–$85B after very strong 2025 growth.
Innovation-Driven Growth: Recent approvals and pipeline progress beyond metabolic disease add new growth pillars. The FDA approval of Kisunla (donanemab) in 2024 and advancement of oral GLP‑1 programs broaden the portfolio.
Gossamer Bio is a San Diego-based company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. Founded by the former Receptos executive team, Gossamer Bio’s strategy will be to leverage an asset-rich in-licensing environment, with a focus on areas of high unmet need, utilizing a team with...
Our mission here at Pacific Health Group is to improve the overall health and wellbeing of the communities we serve. We are committed to providing compassionate, equitable and individualized healthcare, behavioral health services, and social support to enable people to achieve their highest potential for life.
